StockNews.com Begins Coverage on Intra-Cellular Therapies (NASDAQ:ITCI)

StockNews.com began coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research report sent to investors on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock.

ITCI has been the topic of a number of other research reports. Leerink Partnrs cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Mizuho cut Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Ten investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Intra-Cellular Therapies presently has an average rating of “Hold” and an average target price of $106.08.

Intra-Cellular Therapies Trading Up 0.1 %

NASDAQ ITCI opened at $131.60 on Thursday. The business’s 50 day moving average is $127.87 and its two-hundred day moving average is $97.01. Intra-Cellular Therapies has a 12-month low of $64.09 and a 12-month high of $131.60. The stock has a market capitalization of $13.99 billion, a price-to-earnings ratio of -151.26 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Equities analysts forecast that Intra-Cellular Therapies will post -0.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Accredited Wealth Management LLC purchased a new position in shares of Intra-Cellular Therapies during the 4th quarter worth $28,000. True Wealth Design LLC purchased a new position in shares of Intra-Cellular Therapies during the 3rd quarter worth $32,000. GAMMA Investing LLC increased its holdings in shares of Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 240 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth $96,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Intra-Cellular Therapies during the 3rd quarter worth $97,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.